|Podcasts|July 1, 2021
OncView™ Podcast: Front-Line Management of Extensive-Stage SCLC
Author(s)Matthew Fowler
This special edition of the “Oncology Peer Review On-The-Go” podcast hosts Mark Socinski, MD, who discusses important factors in treating and managing extensive-stage small cell lung cancer, and details information from the IMpower133 trial.
Advertisement
As part of the OncView™ video series, CancerNetwork® spoke with Mark Socinski, MD, of the AdventHealth Cancer Institute in Orlando, Florida, about updates in the management of extensive-stage small cell lung cancer (ES-SCLC).
In the video series, Socinski discussed the following:
Epidemiology and Clinical Course of SCLC Evolution of Therapies for SCLC Treatment Challenges in Extensive-Stage SCLC Immunotherapy as First-Line Treatment for Extensive-Stage SCLC The IMpower133 Trial in Extensive-Stage SCLC Extensive-Stage SCLC: Implications of IMpower133
To watch more videos in CancerNetwork®’s OncView™ series, visit
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast wherever you get your podcasts.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer
2
Epcoritamab Combo Shows Sustained Remissions in Follicular Lymphoma
3
What Makes an Optimal CAR T-Cell Therapy Candidate in Multiple Myeloma
4
FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma
5